newsfilter
← Latest News
GlobeNewswire·

Vyant Bio Reports Second Quarter and First Half 2022 Results and Provides Strategic and Business Highlights

Conference Call and Webcast Today at 4:30 pm ET Scientific and Business Highlights Based on preclinical efficacy data in our human Rett cortical organoid model, we are advancing VYNT0126 into clinical trials in Rett patients with encouragement